What is the nSTRIDE Autologous Protein Solution (APS)?
nSTRIDE APS is an autologous (from your own body) therapy which is designed to treat joint pain associated with knee osteoarthritis. In laboratory testing, nSTRIDE APS has been shown to protect cartilage cells. This protective quality may slow the progression of osteoarthritis as well.9^
What is nSTRIDE made of?
nSTRIDE APS processes the patient’s own blood in the doctor’s office to concentrate white blood cells, platelets, and plasma proteins into a small volume of plasma. The output is approximately 2 to 3 ccs of anti-inflammatory solution.
How is nSTRIDE given?
2-3 cc of final output will be injected directly in the knee joint.
Are there any side effects?
You may experience side effects (e.g., bruising, local pain or swelling) associated with the blood draw, knee injection, MRI or X-Ray procedures.
Will nSTRIDE cure my OA?
There is no cure for OA.15 But successful treatment with nSTRIDE APS may reduce or relieve your pain increasing your mobility and comfort.11 Your osteoarthritis may not improve or may get worse.
What are the main benefits of nSTRIDE APS?
May significantly decrease or eliminate pain, reduce stiffness and help restore mobility and flexibility.8*, 11
When will the treatment start to work?
Pain relief can be expected after one week.8*, 11
Is nSTRIDE safe?
Yes. Studies have demonstrated the safety of nSTRIDE APS.8*, 11
Will I be able to be active as usual during the course of my treatment?
It is recommended that you minimize your activity level for 14 days (but not to exceed pre-injection levels).
How long can I expect the benefits to last?
Based on preclinical and early clinical results, patients should expect to see benefits for at least 12 months.8*, 11
Who can be treated?
Patients with mild to moderate knee osteoarthritis can receive nSTRIDE APS therapy.
How many injections are required?
Studies have demonstrated the effectiveness of one injection.8*, 11 Studies suggest one injection will last at least 6-12 months.8*, 11
1. “Knee Pain: MedlinePlus Medical Encyclopedia.” U.S National Library of Medicine. U.S. National Library of Medicine, n.d. Web. 11 Aug. 2014. http:// www.nlm.nih.gov/medlineplus/ency/article/003187.htm.
2. “Research Joint Replacement / Knee Pain Knee Pain Overview.” Knee Pain Overview: Knee Surgery, Partial/Total Knee Joint Replacements. Biomet, n.d. Web. 11 Aug. 2014. <http://www.biomet.com/patients/knee_ overview.cfm>.
3. Nordqvist, Christian. “What Is Arthritis? What Causes Arthritis?” Medical News Today. MediLexicon International, 16 May 2014. Web. 07 Aug. 2014. <http://www.medicalnewstoday.com/articles/7621.php>.
4. “Osteoarthritis in General Practice: Data and Perspectives.” Arthritis Research UK | Arthritis Research UK. Arthritis Research UK | Arthritis Research UK, 19 July 2013. Web. 08 Feb. 2015. <http://www.arthritisresearchuk.org/ policy-and-public-affairs/reports-and-resources/reports.aspx>.
5. “Arthritis of the Knee-OrthoInfo - AAOS.” Arthritis of the Knee-OrthoInfo - AAOS. American Academy of Orthopaedic Surgeons, n.d. Web. 08 Aug. 2014. <http://orthoinfo.aaos.org/topic.cfm?topic=A00212>.
6. Krueger, Pat. “Stages of Osteoarthritis.” EHow. Demand Media, 04 Sept. 2009. Web. 04 Dec. 2014.
7. “Stages of Osteoarthritis: What Everyone Should Know About the Three Stages.” Health Guide Info. N.p., 24 Mar. 2011. Web. 04 Dec. 2014.
8. Bertone AL, Ishihara A, Zekas LJ, et al. Evaluation of a Single Intra-articular Injection of Autologous Protein Solution for Treatement of Osteoarthritis in horses. American Journal of Veterinary Medicine 2014 Feb:75(2):141-151.
9. Matuska A, O’Shaughnessey K, King, W., Woodell-May J, “Autologous solution protects bovine cartilage explants from IL-1a and TNFa-induced cartilage degradation.” Journal of Orthopaedic Research, 2013;31(12):1929-35.
10. O’Shaughnessey K., Matuska A., Hoeppner J., Farr J., Klaassen M., Kaeding C., Lattermann C., King W., Woodell-May J., “An Autologous Protein Solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors,” Journal of Orthopaedic Research, 2014, 32(10):1349-55.
11. van der Weegen W, van Drumpt R, Toler KO, Macenski MM,” Safety and Outcomes Following a Single Autologous Protein Solution injection for Knee Osteoarthritis: A Pilot Study.” International Cartilage Repair Society, #6471, May 8-11, 2015, Chicago, IL.
12. Goldring S.R., Goldring M.B. “The role of cytokines in cartilage matrix degeneration in osteoarthritis.” Clinical Orthopaedics and Related Research, 2004, 427S:S27-S36.
13. Woodell-May J, Matuska A, Oyster M, et al. Autologous protein solution inhibits MMP-13 production by IL-1beta and TNF alpha-stimulated human articular chondrocytes. Journal of Orthopaedic Research, 2011;29(9):1320-6.
14. King WJ, van der Weegen W, van Drumpt R, Soons H, Toler KO, Woodell- May JE,” WBC Concentration Correlates with Increased IL-1ra and Changes in WOMAC Pain Scores in a Safety Study of Autologous Protein Solution.” International Cartilage Repair Society,# 6872, May 8-11, 2015, Chicago, IL.
15. “Osteoarthritis.” : Symptoms & Treatment. Arthritis Foundation, n.d. Web. 20 Apr. 2015. <http://www.arthritis.org/arthritis-facts/disease-center/ osteoarthritis.php>.
* Animal studies are not necessarily indicative of clinical performance
^ Cell culture assays are not necessarily indicative of clinical outcomes